The number of cell and gene therapy (CGT) products approved by the U.S. Food and Drug Administration (FDA) has increased each year, driving up demand for CGT. The intricacy of CGT has proven difficult for conventional software systems to handle, despite advances in drug discovery and therapy development. Conventional software frequently lacks the intelligence and adaptability needed to manage the complexities of CGT. Cell and gene therapy-specific AI platforms can manage complex biological data. AI tools help manufacturers and scientists navigate the complexity of CGT more accurately and efficiently.
The report includes:
- Impact analysis of artificial intelligence (AI) on the global market for cell and gene therapy (CGT) tools and reagents
- Case studies for successful integration of AI and automation in accelerated drug discovery, optimized clinical trials and personalized treatments
- Highlights of AI adoption trends across the major geographical regions as well as disruptions caused by AI across key industry verticals
- Review of AI impact on the various stages of the global supply chain analysis
- Competitive landscape featuring strategic initiatives, market spendings and VC funding outlook
Table of Contents
Chapter 1 Key Use Cases for AI Implementation- Overview
- Key Use Cases
- Use Case 1: AI in Manufacturing
- Use Case 2: AI in Vectors
- Use Case 3: Manufacturing Scalability
- Overview
- Adoption Trends by Region
- Adoption Trends in North America
- Adoption Trends in Europe
- Adoption Trends in the Rest of the World
- Overview
- Impact of AI on Key Industry Verticals in the Cell and Gene Therapy Tools and Reagents Market
- Raw Materials and Media
- Assay and Analytical Tools
- Bioreactor and Process Automation
- Impact of AI on Various Stages of the Value Chain
- Market Spending and Forecasting Analysis
- Abbreviations Used in the Report
Table 1: Abbreviations Used in the Report
List of Figures
Figure 1: Cell and Gene Therapy Value Chain
